Lower cutoff points for Montreal cognitive assessment needed
Jan 17, 2024
A high false-positive rate was seen when used in primary care with a diverse patient population.
Negative wealth shock linked to accelerated cognitive decline
Dec 26, 2023
Associations with accelerated cognitive decline and increased dementia risk were seen for white participants and those aged fewer than 65 years.
More news for Friday, Nov. 3
By
Kimberly Bonvissuto
Nov 03, 2023
Neighoborhood environments can influence modifiable factors for Alzheimer’s, dementias … Former assisted living owner to undergo competency evaluation in exploitation case … Enhanced tai chi program...
CMS officially removes one-time restriction for Alzheimer’s PET scan coverage
By
Aaron Dorman
Oct 17, 2023
Seniors covered by Medicare will now have expanded access to Alzheimer’s diagnostic PET scans after the CMS removed one-time restrictions.
Panel of 48 CSF proteins complements existing Alzheimer’s biomarkers
Sep 07, 2023
The CSF 48 panel plus existing biomarkers significantly improved the diagnostic performance for the outcomes studied.
Study looks at links between anxiety disorders, benzodiazepines, dementia
Aug 14, 2023
Benzodiazepines and anxiety disorders were linked to dementia risk, but no additional risk was seen for benzodiazepines in patients with anxiety disorders.
MIND diet plus caloric restriction no better for cognition
Jul 19, 2023
A small improvement seen in global cognition scores, but it was no different from those following control diet with mild caloric restriction.
Solanezumab does not slow cognitive decline in preclinical Alzheimer’s disease
Jul 19, 2023
The mean change in Preclinical Alzheimer Cognitive Composite score not significantly different at 240 weeks with solanezumab or placebo.
FDA gives full approval to Alzheimer’s disease drug Leqembi
Jul 06, 2023
Although Leqembi did help reduce mental decline compared with placebo, the drug has been linked to two deaths from brain bleeds.
Medicare spending would increase $2.0 to $5.1 billion with lecanemab
May 18, 2023
$2.0 to $5.1 billion would include lecanemab and ancillary costs; estimated annual per-patient coinsurance could reach $6,636